Royal Philips and Salesforce.com are partnering to build a cloud-based platform to advance clinical information sharing and patient engagement. The expectation is that Philips brings to the table its clinical strength with its established medical device, imaging and monitoring presence, while Salesforce.com will contribute its cloud-computing software experience.
Samsung Electronics' digital health strategy relies on a wrist-bound wearable device with cloud-based data-sharing software that enables third-party development of biosensors and medical mobile apps, the company announced May 28 in San Francisco.
Google Ventures' reported $100 million investment in oncology Big Data startup Flatiron Health came to fruition this week. And the deal is even bigger than early reports suggested, with Flatiron raising $130 million and buying electronic medical record business Altos Solutions.
When Flatiron Health emerged in 2012 with a mission to improve oncology care, its founder predicted it would either be "a great success or a horrible failure." Now the Big Data startup is reportedly on the cusp of taking a major step towards the better of these two outcomes, with Fortune writing Google's venture capital wing is leading a $100 million financing round.
The U.K. is seeking feedback on how it should allocate its science and research budget in the coming years.
British government funding groups are looking for startups that will sustain the resurgence in the country's economy. And that means more money for bioinformatics businesses, with the Technology Strategy Board accepting applications for new funding from next month.
Having invested in data analytics platforms in recent years, pharma R&D labs are working to develop the drugs that will justify their spending. But the experience of Merck suggests the costs can be spread across the business, with manufacturing teams finding the data analytics tools as useful as their peers in R&D do.
The features of Berg Pharma's discovery platform read like a bingo card of hyped approaches, with Big Data sitting alongside genomics and artificial intelligence. Berg has tried to push expectations higher still by claiming it can halve drug development time and costs, but to date the claims--like some of the technologies on which they are based--remain unproven.
Big data analytics have become a common consideration in the R&D part of the pharmaceutical industry, allowing researchers to search and share remarkable amounts of data points. But Merck & Co. has turned to the process to solve a manufacturing problem and potentially save hundreds of millions of dollars in the process.
Over the past 18 months the National Institutes of Health has taken multiple steps to get a grip on spiraling Big Data challenges, but the initiatives are still taking shape. And the agency is seeking the input of the genomics, bioinformatics and broader medical communities to help finalize its plans.